Name

Integra Holdings

Legal name

Integra Holdings

Website

https://integra-holdings.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biotech Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Investment Management Advisory (RIA) (FSAEAAAB)

Keywords

• Venture capital
• Biotech investments
• Life sciences holdings
• Academic technology transfer
• Pharmaceutical development

Headquarters

HQ city

Wallisellen

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Investment Returns: Integra Holdings generates returns through equity investments in early-stage life science companies originating from Hebrew University research. They provide funding, strategic planning, business development and R&D guidance to portfolio companies, with returns realized through exits, licensing deals, or ongoing portfolio value.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Integra Holdings is a venture investment and biotech holding company that funds, guides, and commercializes early-stage life science innovations originating from Hebrew University of Jerusalem. It operates a portfolio of nine companies in therapeutic areas including oncology, neurology, respiratory, pain, infectious diseases, inflammation, and ophthalmology, providing equity capital, strategic planning, business development, and R&D guidance from inception through market entry.

Product overview

Integra Holdings is a healthcare investment company that serves as an exclusive gateway for investment in Hebrew University life science early stage research and technologies. Rather than offering a unified product platform, Integra operates a diversified portfolio of 9 portfolio companies spanning Pharma Biotechnology, Medical devices, Diagnostics and AI. The portfolio includes: Ayana Pharma (FDA-approved liposomal cancer therapeutics); Nectin Therapeutics (immune oncology antibodies and ADCs); Splisense (RNA-based antisense oligonucleotide therapies for cystic fibrosis); HighRAD (medical imaging analysis platform); Neoprol (synthetic Propofol formulation); Lipocure (liposomal post-surgical pain treatments); OPhRx (ophthalmic drug delivery); RNAble (FTO inhibitor cancer therapeutics); and Lipomedix (targeted cancer prodrug). Each portfolio company operates independently with its own products, while Integra provides strategic guidance, funding, and commercialization support from inception to market.

Differentiator

Problem solved

Functional benefit

Products and services

• Ayana Pharma Portfolio company developing liposomal therapeutics for cancer treatment. Its FDA-approved product LC 101 (liposomal HCl-Doxorubicin) is used for treatment of ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma, with strategic US marketing handled by Padagis (Perrigo).
• Nectin Therapeutics Portfolio company developing next-generation immune oncology therapies through novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs) that target major escape mechanisms of current immuno-oncology therapies. Aimed at transforming outcomes for cancer patients.
• Splisense Clinical-stage portfolio company developing transformative RNA-based treatments using antisense oligonucleotides (ASOs) for pulmonary diseases including cystic fibrosis and idiopathic pulmonary fibrosis. Raised $28.5 million in Series B in 2021.
• HighRAD Portfolio company operating a quantitative platform for multi-organ tracking in longitudinal volumetric imaging studies (CT/MRI/PET), evaluating disease progression and treatment efficacy using its novel Region of Difference (ROD) technology.
• Neoprol Preclinical-stage portfolio company developing NP-09, an improved synthetic formulation of Propofol that addresses contamination risks associated with current animal and plant-derived Propofol products.
• Lipocure Preclinical-stage portfolio company developing novel liposomal drug candidates for post-surgical pain, including LC400, a novel liposomal hydrogel formulation of Bupivacaine.
• OPhRx Preclinical-stage portfolio company developing novel topical drug products for front-of-the-eye and back-of-the-eye diseases using lyotropic liquid crystals drug delivery technology. Lead candidates include OPH-101 for wet AMD and OPH-100 for Dry Eye Syndrome.
• RNAble Preclinical-stage portfolio company developing first-in-class small-molecule FTO inhibitors targeting cancers characterized by chromosomal instability (CIN). Lead candidate RNB-1720 exhibits oral bioavailability with confirmed efficacy across multiple CIN+ cancer models.
• Lipomedix Early-stage portfolio company developing Promitil-Pegylated Liposomal Mitomycin C Prodrug (PL-MLP), an innovative agent for targeted cancer therapy that overcomes MMC toxicity tolerability issues. Aimed at gastrointestinal-derived cancers including stomach, pancreatic, and colorectal.

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and major.

• EvoteccoreStrategic or Co-development Partner · 1 October 2019LAB555 is the first academic BRIDGE Partnership in Israel, translating early-stage research from Hebrew University into industrial drug development. Leverages Integra's skill in identifying promising early-stage therapeutic projects, Yissum's translational expertise, and Evotec's industrial drug development platform.
• YissumcoreStrategic or Co-development PartnerYissum is the technology transfer company of Hebrew University and Integra Holdings' founding parent. Yissum founded Integra Holdings in 2012 and provides exclusive access to Hebrew University's life science innovations. Yissum ranks among top technology transfer companies globally with over 8,900 patents and 2,500 inventions.
• Padagis (Perrigo)majorChannel Partner/ Reseller/ DistributorAyana Pharma, an Integra portfolio company, has strategic agreement with Padagis for marketing of FDA-approved liposomal therapeutics in the US. Padagis was acquired by Altris for approximately $55.1 billion and has sales of hundreds of products in US and Israel.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• aMoon Fund: Israeli life sciences and healthtech venture fund; led Nectin Therapeutics' Series B alongside Integra. Closely comparable in fund size, focus area, and Israeli biotech origination strategy.
• SR One: Biotech-focused venture firm (GSK-affiliated) that has co-invested with Integra in portfolio companies such as Atox Bio. Comparable as a biotech-dedicated investor with similar therapeutic focus.
• Pontifax: Israeli healthcare-dedicated venture firm co-investing with Integra across Hebrew University spin-outs (e.g., Avraham Pharmaceuticals). Operates with a similar thesis of bridging Israeli academic innovation to commercial biotech.
• Lundbeckfond Ventures: Healthcare/biotech investment arm of the Lundbeck Foundation; co-investor with Integra in Atox Bio. Comparable as a sector-focused, European-anchored biotech VC.
• Israel Biotech Fund (IBF): Specialist Israeli biotech venture investor participating alongside Integra in rounds like Splisense. Directly comparable as a sector-focused Israeli biotech VC.
• OrbiMed Israel: Israeli arm of the global OrbiMed healthcare investment platform; co-invested with Integra in Splisense and Atox Bio. Comparable as a biotech-dedicated VC investing in Israeli innovation.
• BioLight Life Sciences Investments: Israeli life sciences investment company that jointly established OPhRx with Integra. Comparable as a portfolio-style Israeli life sciences holding/investment company.
• Clal Biotechnology Industries (CBI): Israeli biotech holding company co-investing with Integra in Avraham Pharmaceuticals. Comparable structure as a publicly-affiliated biotech investment vehicle operating in the Israeli ecosystem.

Broad incumbents

• Johnson & Johnson Innovation (JJDC): Global corporate venture arm of J&J with deep biotech and academic spin-out activity. Comparable at a thematic level as a large-scale investor in early-stage biotech innovation arising from academic research, though with vastly broader scope and capital base.
• Yissum Research Development Company: Hebrew University's technology transfer company and Integra's founding parent. Comparable as a broader tech transfer and commercialization vehicle, but with much wider scope beyond life sciences and beyond pure venture investing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries9 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integra Holdings